期刊文献+

原发性肝细胞癌CDC25A的表达与多普勒超声影像特征的关联性分析 被引量:2

Correlation between expression of CDC25A and Doppler ultrasound features in primary hepatocellular carcinoma
下载PDF
导出
摘要 目的:检测细胞分裂周期蛋白25A(cell division cycle 25A,CDC25A)基因在原发性肝细胞癌组织中的表达,探讨其与肝癌多勒超声影像特征的关联.方法:运用RT-PCR和Western blot的方法检测86例肝癌组织及对应癌旁组织中CDC25A基因的表达;用B超观察肝癌患者肝脏肿瘤影像学特征.结果:在86例肝癌病例中,75.58%(65/86)的肝癌组织CDC25A mRNA和蛋白表达明显高于对应癌旁组织(P<0.05);肝癌组织中CDC25A的表达与多普勒超声影像特征如肿瘤的大小、血流分级、血流阻力指数及门静脉侵袭情况明显相关(P<0.05),与肝脏肿瘤结节的个数无关(P>0.05).结论:CDC25A基因可能在肝癌的发生及转移过程中发挥重要作用,肝癌组织中CDC25A基因的表达与超声影像相结合可为肝癌临床治疗及预后判断提供理论依据. AIM: To investigate the expression of cell division cycle 25A (CDC25A) in primary hepatocellular carcinoma (PHC) and to explore its relationship with Doppler ultrasound imaging features. METHODS: The expression of CDC25A in 86 PHC specimens and matched tumor-adjacent tissue specimens was detected by RT-PCR and Western blot. The imaging features of PHC was analyzed by Doppler ultrasound. RESULTS: CDC25A was found to be overexpressed in 75.58% (65/86) of PHC cases (P 〈 0.05). The expression of CDC25A protein was signi?cantly correlated with Doppler ultrasound imaging features including tumor size, blood flow grade, resistance index (RI) and portal vein invasion (all P 〈 0.05), but not with the number of liver tumor nodes (P 〉 0.05). CONCLUSION: CDC25A may play an important role in the development and metastasis of PHC. Detection of CDC25A expression combined with ultrasound imaging may be used clinically for evaluation of treatment response and prognosis in PHC patients.
出处 《世界华人消化杂志》 CAS 北大核心 2013年第26期2649-2654,共6页 World Chinese Journal of Digestology
基金 南昌市指导性科技计划基金资助项目 No.(2012)120号-9~~
关键词 CDC25A 原发性肝细胞癌 超声 CDC25A Primary hepatocellular carcinoma Ultrasonography
  • 相关文献

参考文献2

二级参考文献14

  • 1Olivier Mir,Romain Coriat,Pascaline Boudou-Rouquette,Stanislas Ropert,Jean-Philippe Durand,Anatole Cessot,Vincent Mallet,Philippe Sogni,Stanislas Chaussade,Stanislas Pol,Fran?ois Goldwasser.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib[J].Medical Oncology.2012(4)
  • 2Romain Coriat,Olivier Mir,Anatole Cessot,Catherine Brezault,Stanislas Ropert,Jean-Philippe Durand,Wulfran Cacheux,Stanislas Chaussade,Fran?ois Goldwasser.Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients[J].Investigational New Drugs.2012(1)
  • 3Goldberg RM,Sargent DJ,Morton RF,et al.A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[].Journal of Clinical Oncology.2004
  • 4Llovet JM,Bustamante J,Castells A,et al.Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[].Hepatology.1999
  • 5Hollebecque A,Cattan S,Romano O,Sergent G,MouradA,Louvet A,Dharancy S,Boleslawski E,Truant S,PruvotFR,Hebbar M,Ernst O,Mathurin P.Safety and efficacy ofsorafenib in hepatocellular carcinoma:the impact of theChild-Pugh score[].Alimentary Pharmacology and Therapeutics.2011
  • 6YZ Patt,MM Hassan,A Aguayo,AK Nooka,RD Lozano,SA Curley,JN Vauthey,LM Ellis,II Schnirer,RA Wolff,C Charnsangavej,TD Brown.Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma[].Cancer.2004
  • 7Qin SK,Bai Y,Sun Y,et al.Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX 4)versus doxorubicin as palli-ative systemic chemotherapy in advanced HCC in Asian pts[].Journal of Clinical Oncology.2010
  • 8JO Lee,KW Lee,DY Oh,JH Kim,SA Im,TY Kim,YJ Bang.Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma[].Annals of Oncology.2009
  • 9HO C,NG K,O’REILLY Set al.Outcomes in elderly patientswith advanced colorectal cancer treated with capecitabine:a popu-lation-based analysis[].Clinical Colorectal Cancer.2005
  • 10YH Chung,IH Song,BC Song,GC Lee,MS Koh,HK Yoon.Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis[].Cancer.2000

共引文献9

同被引文献19

  • 1Krauss G. Biochemistry of signal transduction and regula-tion[M].3版.北京:化学工业出版社,2005:321-324.
  • 2Hoffmann I, Draetta G, Karsenti E. Activation of the phos-phatase activity of human Cdc25A by a CDK2-cyclin E depen-dent phosphorylation at the Gl/S transition [J]. EMBO J, 1994,13(18):4302-4310.
  • 3Bistros R, Lobjois V, Ducommun B. Cdc25 phosphatases incancer cells: key players? Good targets? [J]. Nat Rev Cancer,2007,7(7):495-507.
  • 4Xu X, Yamamoto H, Sakon M, et al. Overexpression of Cdc25Aphosphatase is associated with hypergrowth activity and poorprognosis of human hepatocellular carcinomas [J]. Clin CancerRes, 2003,9(5):1764-1772.
  • 5Xu X,Yamamoto H,Liu G, et al. CDC25A inhibition suppress-es the growth and invasion of human hepatocellular carcinomacells [J]. Int J Mol Med, 2008,21(2) : 145-152.
  • 6Shen T, Huang S. The role of Cdc25A in the regulation of cell proliferation and apoptosis [ J ]. Anticancer Agents Med Chem, 2012, 12(6) :631-639.
  • 7Krauss G. Biochemistry of signal transduction and regula-tion[M].第3版.北京:化学工业出版社,2005.321-324.
  • 8Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human Cdc25A by a CDK2-cyclin E dependent phosphorylation at the GI/S transition [ J ]. EMBO J, 1994, 13(18) :4302-4310.
  • 9Leisser C, Rosenberger G, Maier S, et al. Subcellular lo- calization of Cdc25A determines cell fate [ J]. Cell Death Differ, 2004, 11 ( 1 ) : 80-89.
  • 10Brunetto El, Ferrara AM, Rampoldi F, et al. CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment[ J].Neoplasia, 2013, 15 (6) :579-590.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部